HomePipeline News Join Us Contact

News.

Press Releases and In the Media — recent updates from Syntic Life.

June 30, 2026

Syntic Life Reports Positive Cellular-Rejuvenation Results in Mouse Models

Syntic Life

Restoring the biology of youth, one cell at a time. We are developing gene therapies that target the root biology of aging — the single largest modifiable risk factor for chronic disease. By partially restoring the epigenetic markers that organize how cells work, our platform is designed to reverse cellular age, renewing many tissues and addressing age-related conditions at their source. In mouse studies, our lead approach restored markers of cellular age toward a younger state, with no adverse safety signals observed at the doses tested. Headquartered in the USA, with labs in Rotan, China, and India.

Company

About Us News Join Us Contact

Platform

Our Platform Pipeline The Science Syntic AI

Resources

Data & Attribution

Connect

LinkedIn lab@syntic.ai

© 2026 Syntic AI Inc. All rights reserved.·Privacy Policy·Terms of Use·Syntic Life's technologies are in preclinical development and are not approved for human use.

Syntic Life's technologies are in preclinical development and are not approved for human use. Results described were obtained in laboratory and animal models and do not predict outcomes in humans. All research is conducted in compliance with applicable institutional, ethical, and regulatory standards. Statements regarding our research, pipeline, and vision are forward-looking and reflect current scientific hypotheses, not clinical outcomes or regulatory approvals.